Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Arbekacin (ABK) is an aminoglycoside that exhibits anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-Pseudomonas aeruginosa activities. Therefore, for patients with febrile neutropenia (FN) and concurrent pneumonia suspected to be caused by MRSA, ABK may be sufficiently effective even as a single agent. Materials and methods: Patients with hematologic malignancies treated with ABK who met the following criteria were included: 1) fever during neutropenia or functional neutropenia, 2) FN complicated by pneumonia, and 3) possible infection by antimicrobial-resistant Gram-positive cocci. Results: This study encompassed 22 episodes involving 19 patients, of which, 15 (68.2%) were successfully treated with ABK. Of the nine episodes showing inadequate response to other anti-MRSA drugs, eight were successfully treated with ABK. Grade 2 or worse adverse events included acute kidney injury (13.6%) and increased transaminase levels (9.1%). Conclusion: The present study demonstrated that ABK is effective and safe in patients with FN and concurrent pneumonia caused by antimicrobial-resistant Gram-positive cocci. ABK may also be effective in patients who are unresponsive to other anti-MRSA drugs. Therefore, ABK may be beneficial in the treatment of pneumonia caused by antimicrobial-resistant Gram-positive cocci in patients with FN.
Abstract
Background: Arbekacin (ABK) is an aminoglycoside that exhibits anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-Pseudomonas aeruginosa activities. Therefore, for patients with febrile neutropenia (FN) and concurrent pneumonia suspected to be caused by MRSA, ABK may be sufficiently effective even as a single agent. Materials and methods: Patients with hematologic malignancies treated with ABK who met the following criteria were included: 1) fever during neutropenia or functional neutropenia, 2) FN complicated by pneumonia, and 3) possible infection by antimicrobial-resistant Gram-positive cocci. Results: This study encompassed 22 episodes involving 19 patients, of which, 15 (68.2%) were successfully treated with ABK. Of the nine episodes showing inadequate response to other anti-MRSA drugs, eight were successfully treated with ABK. Grade 2 or worse adverse events included acute kidney injury (13.6%) and increased transaminase levels (9.1%). Conclusion: The present study demonstrated that ABK is effective and safe in patients with FN and concurrent pneumonia caused by antimicrobial-resistant Gram-positive cocci. ABK may also be effective in patients who are unresponsive to other anti-MRSA drugs. Therefore, ABK may be beneficial in the treatment of pneumonia caused by antimicrobial-resistant Gram-positive cocci in patients with FN.
참고문헌 (40)
- Klastersky J, "The multinational association for supportive care in cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients", J Clin Oncol, 18, pp.3038~3051 (2000)
- Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america", Clin Infect Dis, 52, pp.e56~93 (2011)
- Klastersky J, "Concept of empiric therapy with antibiotic combinations. Indications and limits", Am J Med, 80, pp.2~12 (1986)
- SchimpffS, "Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia", N Engl J Med, 284, pp.1061~1065 (1971)
- Yoshida M, "Analysis of bacteremia", fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group, 2011, pp.93, 66~73
- Steinkraus G, "Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus(VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus(MRSA)blood isolates from 2001-05", J Antimicrob Chemother, 60, pp.788~794 (2007)
- Kehrmann J, "Vancomycin MIC creep in MRSA blood culture isolates from Germany : a regional problem?", Eur J Clin Microbiol Infect Dis, 30, pp.677~683 (2011)
- Zhuo C, "Glycopeptide minimum inhibitory concentration creep among meticillin-resistant Staphylococcus aureus from 2006-2011 in China", Int J Antimicrob Agents, 41, pp.578~581 (2013)
- Takesue Y, "Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg", ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia, 2011, pp.17, 52~57
- Jacob JT, "High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections : a meta-analysis", Int J Infect Dis, 17, pp.e93~e100 (2013)
- Yamada K, "Clinical characteristics of methicillin-resistant coagulase-negative staphylococcal bacteremia in a tertiary hospital", Intern Med, 56, pp.781~785 (2017)
- Kato D, "In vitro susceptibilities of clinical isolates of coagulasenegative staphylococci to glycopeptide antibiotics", Jpn J Antibiot, 51, pp.735~745 (1998)
- Nakamura T, "Drug sensitivity and teicoplanin resistance of coagulase-negative Staphylococcus isolated from blood culture", Kansenshogaku Zasshi, 78, pp.46~53 (2004)
- "The Japanese Association for Infectious Diseases. Practice guidelines for the management and treatment of infections caused by MRSA. 2019 Edition"[URL]
- American Thoracic Society, "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia", Am J Respir Crit Care Med, 171, pp.388~416 (2005)
- Yuasa A, "Postmarketing surveillance of linezolid", Jpn J Chemother, 65, pp.491~509 (2017)
- Watanabe T, "Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus", J Antimicrob Chemother, 39, pp.471~476 (1997)
- Kurazono M, "Epidemiological survey of drug resistance of methicillinresistant Stapylococcus aureus isolated in Japan in 2000", Jpn J Chemother, 50, pp.494~499 (2002)
- Watanabe A, "Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009 : general view of the pathogens’ antibacterial susceptibility", J Infect Chemother, 18, pp.609~620 (2012)
- Fujimura S, "Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007", Jpn J Chemother, 57, pp.91~96 (2009)
- Nakamura I, "New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa", Eur J Clin Microbiol Infect Dis, 34, pp.83~87 (2015)
- Araoka H, "In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan", Jpn J Infect Dis, 65, pp.84~87 (2012)
- 이지영, "Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus", Journal of Korean Medical Science, 21(2), pp.188~192 (2006), 대한의학회
- Miura K, "Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies", Int J Hematol, 103, pp.334~340 (2016)
- "Clinical evaluation methods for new antimicrobial agents to treat respiratory infections (2nd version)"[URL]
- Masaoka T, "Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan : executive summary", Clin Infect Dis, 39(Suppl 1), pp.S49~S52 (2004)
- "Common terminology criteria of adverse events (CTCAE)"[URL]
- Kanda Y, "Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics", Bone Marrow Transplant, 48, pp.452~458 (2013)
- Matsumoto T, "Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia : a multi-institutional study", J Infect Chemother, 19, pp.128~137 (2013)
- Hwang JH, "The usefulness of arbekacin compared to vancomycin", Eur J Clin Microbiol Infect Dis, 31, pp.1663~1666 (2012)
- Shimizu K, "Actual use of antiMRSA drugs in Japan with the focus on arbekacin", Japanese Journal of Chemotherapy, 51, pp.717~730 (2003)
- Trifilio S, "Aztreonam and vancomycin for initial treatment of febrile neutropenia in penicillinallergic patients during hematopoietic stem cell transplantation", J Adv Pract Oncol, 10, pp.685~690 (2019)
- Hahn-Ast C, "An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia : is the different toxicity profile clinically relevant?", Infection, 36, pp.54~58 (2008)
- Jaksic B, "Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer", Clin Infect Dis, 42, pp.597~607 (2006)
- 이재훈, "Clinical Usefulness of Arbekacin", Infection and Chemotherapy, 48(1), pp.1~11 (2016), 대한감염학회
- "Package insert of Habekacin® Injection,version 8, 2015"[URL]
- "Clinical practice guidelines for therapeutic drug monitoring for antibiotics"[URL]
- Shi MM, "Inoculation pneumonia caused by coagulase negative Staphylococcus", Front Microbiol, 10, pp.2198~ (2019)
- Mermel LA, "Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 Update by the Infectious Diseases Society of America", Clin Infect Dis, 49, pp.1~45 (2009)
- Cook RJ, "Septic pulmonary embolism : presenting features and clinical course of 14 patients", Chest, 128, pp.162~166 (2005)